| 11. |
|
|
| 12. |
|
|
| 13. |
|
|
| 14. |
|
|
| 15. |
- Seddique, A. A., et al.
(författare)
-
Sources of U and Th in groundwater of the paleobeach aquifer at Cox's Bazar, Southeast Bangladesh
- 2020
-
Ingår i: Groundwater for Sustainable Development. - : Elsevier B.V.. - 2352-801X. ; 10
-
Tidskriftsartikel (refereegranskat)abstract
- To explore the influence of radioactive heavy minerals on thorium (Th) and uranium (U) contamination in groundwater, we performed geochemical and mineralogical investigations of core samples (from the ground surface to 18.9 m depth) from a paleobeach area in Cox's Bazar, southeastern Bangladesh. Geochemical data document elevated levels of total Th (6.3–202.3 mg/kg, average 32.9 mg/kg) and U (1.1–33.4 mg/kg, average 5.2 mg/kg), and lithological observations document monazite concentrations as great as 2.36 wt% and zircon concentrations as great as 3.82 wt%. These minerals were found in organic-rich fine to very fine sand in the uppermost meter of the sediment column (down to 1.2 m depth) rather than in coarser sandy sediment. Energy-dispersive spectroscopy of several monazite and zircon grains indicated that alteration was greater in oxic sediment (down to 3 m depth) than reduced sediment (deeper than 3 m). Monazite and zircon had relatively high concentrations of Th (3395.9–3937.5 mg/kg and 275.5–318.4 mg/kg, respectively) and U (850.7–990.6 mg/kg and 256.3–290.5 mg/kg, respectively). Chemical weathering (dissolution and reprecipitation) of detrital monazite and zircon grains, which releases U and Th into the groundwater, may be a major and growing concern for drinking water in the study area. Shallow tubewells (<20 m depth) waters were enriched in U (0.09–9.57 μg/L) and Th (0.02–127.09 µg/L) and that the enrichment mostly occurred in highly oxic environments (Eh = 0.35–0.5 V). We suggest that hydrological and biogeochemical conditions in the aquifer that follow land-use changes influence the release of Th and U into the groundwater of the study area.
|
|
| 16. |
- Christakoudi, Sofia, et al.
(författare)
-
Development and validation of the first consensus gene-expression signature of operational tolerance in kidney transplantation, incorporating adjustment for immunosuppressive drug therapy
- 2020
-
Ingår i: EBioMedicine. - : Elsevier BV. - 2352-3964. ; 58
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Kidney transplant recipients (KTRs) with "operational tolerance" (OT) maintain a functioning graft without immunosuppressive (IS) drugs, thus avoiding treatment complications. Nevertheless, IS drugs can influence gene-expression signatures aiming to identify OT among treated KTRs. Methods: We compared five published signatures of OT in peripheral blood samples from 18 tolerant, 183 stable, and 34 chronic rejector KTRs, using gene-expression levels with and without adjustment for IS drugs and regularised logistic regression. Findings: IS drugs explained up to 50% of the variability in gene-expression and 20-30% of the variability in the probability of OT predicted by signatures without drug adjustment. We present a parsimonious consensus gene-set to identify OT, derived from joint analysis of IS-drug-adjusted expression of five published signature gene-sets. This signature, including CD40, CTLA4, HSD11B1, IGKV4-1, MZB1, NR3C2, and RAB40C genes, showed an area under the curve 0.92 (95% confidence interval 0.88-0.94) in cross-validation and 0.97 (0.93-1.00) in six months follow-up samples. Interpretation: We advocate including adjustment for IS drug therapy in the development stage of gene-expression signatures of OT to reduce the risk of capturing features of treatment, which could be lost following IS drug minimisation or withdrawal. Our signature, however, would require further validation in an independent dataset and a biomarker-led trial. (c) 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license. (http://creativecommons.org/licenses/by/4.0/)
|
|
| 17. |
|
|
| 18. |
- McGreevy, David, 1988-, et al.
(författare)
-
Feasibility and Clinical Outcome of Reboa in Patients with Impending Traumatic Cardiac Arrest
- 2020
-
Ingår i: Shock. - : Lippincott Williams & Wilkins. - 1073-2322 .- 1540-0514. ; 54:2, s. 218-223
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) may improve Systolic Blood Pressure (SBP) in hypovolemic shock. It has, however, not been studied in patients with impending traumatic cardiac arrest (ITCA). We aimed to study the feasibility and clinical outcome of REBOA in patients with ITCA using data from the ABOTrauma Registry.METHODS: Retrospective and prospective data on the use of REBOA from 16 centers globally were collected. SBP was measured both at pre- and post-REBOA inflation. Data collected included patients' demography, vascular access technique, number of attempts, catheter size, operator, zone and duration of occlusion, and clinical outcome.RESULTS: There were 74 patients in this high-risk patient group. REBOA was performed on all patients. A 7-10Fr catheter was used in 66.7%, 58.5% were placed on the first attempt, 52.1% through blind insertion and 93.2% inflated in Zone I, 64.8% for a period of 30 to 60 minutes, 82.1% by ER doctors, trauma surgeons or vascular surgeons. SBP significantly improved to 90 mmHg following the inflation of REBOA. 36.6% of the patients survived.CONCLUSIONS: Our study has shown that REBOA may be performed in patients with ITCA, SBP can be elevated and 36.6% of the patients survived if REBOA placement is successful.
|
|
| 19. |
- Åberg, Anna-Maja, et al.
(författare)
-
High monocyte count and expression of s100a9 and s100a12 in peripheral blood mononuclear cells are associated with poor outcome in patients with metastatic prostate cancer
- 2021
-
Ingår i: Cancers. - : MDPI. - 2072-6694. ; 13:10
-
Tidskriftsartikel (refereegranskat)abstract
- Increasing evidence indicates calcium-binding S100 protein involvement in inflammation and tumor progression. In this prospective study, we evaluated the mRNA levels of two members of this family, S100A9 and S100A12, in peripheral blood mononuclear cells (PBMCs) in a cohort of 121 prostate cancer patients using RT-PCR. Furthermore, monocyte count was determined by flow cytometry. By stratifying patients into different risk groups, according to TNM stage, Gleason score and PSA concentration at diagnosis, expression of S100A9 and S100A12 was found to be significantly higher in patients with metastases compared to patients without clinically detectable metastases. In line with this, we observed that the protein levels of S100A9 and S100A12 in plasma were higher in patients with advanced disease. Importantly, in patients with metastases at diagnosis, high monocyte count and high levels of S100A9 and S100A12 were significantly associated with short progression free survival (PFS) after androgen deprivation therapy (ADT). High monocyte count and S100A9 levels were also associated with short cancer-specific survival, with monocyte count providing independent prognostic information. These findings indicate that circulating levels of monocytes, as well as S100A9 and S100A12, could be biomarkers for metastatic prostate cancer associated with particularly poor prognosis.
|
|
